Case Report: Discordance between RNA-identified ETV6::RET and clinically reportable DNA profiling in salivary gland secretory carcinoma. (PubMed, Front Oncol) - Oct 10, 2026 - "We report a patient with an ETV6::RET-positive tumor who achieved a complete response to pralsetinib and subsequently developed resistance. Research WTS did not constitute an approved companion diagnostic result, and the approved DNA report did not establish an actionable ETV6::RET finding; selpercatinib was therefore not initiated. When DNA profiling yields unresolved rearrangement signals, a clinically validated RNA-based fusion assay and an appropriate regulatory framework for treatment selection may improve access to matched therapy."
Journal • Oncology • Salivary Gland Cancer • Solid Tumor • Thyroid Gland Carcinoma • ETV6 • RET
|
|
Bunya Kuze; Hideaki Bando; Hironaga Satake; Hisateru Yasui; Koushiro Ohtsubo; Masao Yagi; Milan Radovich; Riu Yamashita; Shigenori Kadowaki; Shogen Boku; Susumu Okano; Takao Fujisawa; Takayuki Yoshino; Taro Shibuki; Tomofumi Sakagami; Tomoyuki Otsuka; Yasushi Shimizu; Yoshiaki Nakamura
|